Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

NCT02691728 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: LDV/SOF FDC

Sponsor

Peter J. Ruane, M.D., Inc.

Collaborators

[object Object]